Basal Insulin Requirement Is ~30% of the Total Daily Insulin Dose in Type 1 Diabetic Patients, Who Use the Insulin Pump

Akio Kuroda, MD¹
Hideaki Kaneto, MD¹
Tetsuyuki Yasuda, MD¹
Munehide Matsuhisa, MD²
Kazuyuki Miyashita, MD¹
Noritaka Fujiki, MD¹
Keiko Fujisawa, MD¹
Tsunehiko Yamamoto, MD¹
Mitsuosah Takahara, MD¹
Fumie Sakanoto, MD¹
Takaaki Matsuoka, MD¹
Ichiro Shimomura, MD¹

OBJECTIVE—To investigate the basal insulin requirement in total daily insulin dose in Japanese type 1 diabetic patients, who use the insulin pump.

RESEARCH DESIGN AND METHODS—The basal insulin requirement in type 1 diabetic patients without detectable C-peptide using the insulin pump (Paradigm 712) was investigated during 2–3 weeks of hospitalization. The patients were type 1 diabetic patients without detectable C-peptide who were consecutively selected who met the inclusion and exclusion criteria and who signed an informed consent. We used a Paradigm 712 pump (Medtronic, Northridge, CA) with which we program basal insulin infusion hourly every 0.05 units.

RESULTS—Total daily insulin dose was 31.6 ± 8.5 units, and total basal insulin requirement was 8.7 ± 2.9 units, which was 27.7 ± 6.9% of the total daily dose.

CONCLUSIONS—Basal insulin requirement is ~30% of the total daily dose in Japanese type 1 diabetic patients, who use the insulin pump.

Insulin therapy consists of basal insulin to keep blood glucose level stable and bolus insulin to control postprandial hyperglycemia and to correct hyperglycemia if necessary. Type 1 diabetic patients who run out of their own insulin secretion are recommended to set proper amounts of basal insulin. According to the textbook, total basal insulin dose (TBD) is ∼50% of the total daily insulin dose (TDD) (1–3).

The purpose of this study was to assess basal insulin requirement in type 1 diabetic patients, who are on insulin pump therapy, without detectable C-peptide (<0.1 ng/mL). This study was done during 2–3 weeks of hospitalization in patients on diabetic diets.

The average of the eight-point blood glucose levels during the 2–3 weeks of hospitalization, an eight-point glucose testing (before and 2 h after each meal [2200, 0300, and 0700 h]) was performed to allow optimization of basal insulin rates according to the previous report (4). The diabetic meals in all studies were 25–30 kcal/kg ideal body weight, consisting of 50–60% carbohydrate, 15–20% protein, and 20–25% fat and were prepared by dietitians. Overnight basal insulin rates were evaluated with the blood glucose readings at 2200, 0300, and 0700 h and set using the same method (4). Upon verification of the basal rates, bolus insulin was determined by physicians using carbohydrate counting. All meals were consumed within 20 min; no additional food or drink was consumed unless required to treat hypoglycemia. The target fasting glucose and 2-h postprandial glucose values were set at 100 mg/dL before each meal and 150 mg/dL at 2 h after each meal.

RESULTS—Total daily insulin dose was 31.6 ± 8.5 units, and total basal insulin requirement was 8.7 ± 2.9 units, which was 27.7 ± 6.9% of the total daily dose.

CONCLUSIONS—Basal insulin requirement is ~30% of the total daily dose in Japanese type 1 diabetic patients, who use the insulin pump.

From the ¹Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan; and the ²Diabetes Clinical Research and Development Center, Tokushima University, Tokushima, Japan. Corresponding author: Akio Kuroda, kurodaakio@gmail.com.

Received 15 November 2010 and accepted 14 February 2011.

DOI: 10.2337/dc10-2149

© 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
Basal insulin requirement in type 1 diabetes

We consider that previous estimation (TBD = 0.5 × TDD) might have been influenced by several factors as follows. One is diet failure, i.e., increased fat intake. Fat ingestion may cause delay of gastric emptying, leading to late glucose excursion (7). When eating fat-rich pizza, it was recommended to give dual-wave bolus insulin for 8 h, which means giving bolus insulin for 8 h after normal bolus insulin to suppress late glucose excursion induced by fat (8). The basal insulin requirement in the daily life after discharge might be more than in the hospital if patients eat more fat than recommended. However, %TBD stayed at the same level without deteriorating glucose control 6 months after the study period.

CONCLUSIONS—We investigated here the basal insulin requirement in C-peptide-negative type 1 diabetic patients. Our results show that basal insulin requirement is ~30% TDD in the inpatients on diabetic diets prepared by a dietitian. In addition, the maximal basal insulin requirement in all patients was 43.8% TDD, and no patients required 50% TDD. These results indicate the currently widely published formula (TBD = 0.5 × TDD) (1–3) overestimates the TBD. King (5) also recently suggested that this should be revised to TBD = 0.4 × TDD to prevent excess basal insulin treatment. In our results, TBD was ~30% TDD, which was less than King’s estimation. We assume that this is the result of the strict diabetic diet in the hospital setting. Diabetic meals are served to all patients. These meals are close to the macronutrient content as the meals recommended by the American Diabetes Association (6).

We did not use a continuous glucose monitoring system (CGMS) in our study. Although there is a report showing that eight-point glucose testing a day is comparable to a continuous glucose monitoring system, eight-point glucose testing has the possibility of missing midnight hypoglycemia (9). In such a case, it might be better to further reduce the TBD. Furthermore, this study is of small size and is not designed to be a randomized study comparing different percentages of basal and bolus.

In conclusion, basal insulin requirement is ~30% TDD in Japanese type 1 diabetic patients, who use the insulin pump.

Acknowledgments—No potential conflicts of interest relevant to this article were reported.

A.K. and H.K. researched data and wrote the manuscript. T.Y., M.M., and K.M. reviewed/editied the manuscript. N.F., K.F., and T.Y. researched data. M.T., F.S., and T.M. edited the manuscript. I.S. researched data and contributed to discussion.

References
1. Davidson PC, Hebblewhite HR, Steed RD, Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract 2008;14:1095–1101
2. Sherr J, Tamborlane W, Bode B. Insulin Pump Therapy in Therapy for Diabetes Mellitus and Related Disorders. 5th ed. Lebovitz H, Ed. Alexandria, VA, American Diabetes Association, 2009, p. 322–331
3. Wolpert H. Smart Pumping for People with Diabetes. Wolpert H, Ed. Alexandria, VA, American Diabetes Association, 2002
4. Scheiner G, Boyer BA. Characteristics of basal insulin requirements by age and gender in type-1 diabetes patients using insulin pump therapy. Diabetes Res Clin Pract 2005;69:14–21
5. King AB. How much do I give? Reevaluation of insulin dosing estimation formulas using continuous glucose monitoring. Endocr Pract 2010;16:428–432
6. Warshaw H, Bolderman K. Practical Carbohydrate Counting: A How-to-Teach Guide for Health Professionals. 2nd ed. American Diabetes Association, 2009
7. Welch IM, Bruce C, Hill SE, Read NW. Duodenal and ileal lipid suppresses postprandial blood glucose and insulin responses in man: possible implications for the dietary management of diabetes mellitus. Clin Sci (Lond) 1987;72:209–216
8. Jones SM, Quarry JL, Caldwell-McMillan M, Mauer DT, Gabbay RA. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system. Diabetes Technol Ther 2005;7:233–240
9. Fiallo-Scharer R; Diabetes Research in Children Network Study Group. Eight-point glucose testing versus the continuous glucose monitoring system in evaluation of glycemic control in type 1 diabetes. J Clin Endocrinol Metab 2003;90:3387–3391